Clinical Trials

MyeloidOther hematologic neoplasm

99 enrolled

Leukemia, Myelodysplastic Syndromes

NCT05268003 2026-03-05

A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia

26 enrolled

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04416984 2026-03-04

ALPHA2

160 enrolled

Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05479994 2026-03-04

Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

100 enrolled

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03974217 2026-02-25

Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts

13 enrolled

Leukemia

NCT00544466 2026-02-19

Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies

LymphoidMyeloidOther hematologic neoplasm

75 enrolled 8 charts

Congenital Abnormalities, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02677922 2026-02-19

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

130 enrolled 38 charts

Leukemia, Leukemia, Myeloid, Acute

NCT04571138 2026-02-18

A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma

42 enrolled

Leukemia, Lymphoma

NCT03410875 2026-02-12

A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia

30 enrolled

Leukemia, Leukemia, Hairy Cell

NCT04977024 2026-02-11

SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

LymphoidOther hematologic neoplasmPlasma cell

63 enrolled

COVID-19, Leukemia, Lymphoma, Multiple Myeloma

NCT05456191 2026-02-06

ASC4START

Phase 3 Active not recruiting

568 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06001385 2026-02-05

OPTIMIZE

LymphoidMyeloidOther hematologic neoplasmOther neoplasm

313 enrolled

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Leukemia, Myeloid, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Precancerous Conditions, Preleukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT06053268 2026-02-05

Mindfulness Interventions to Improve Health Activation, Coping, and Stress Among Childhood Cancer Survivors

Phase NA Active not recruiting

50 enrolled

Leukemia, Lymphoma, Neoplasms

NCT03059485 2026-02-04

DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission

82 enrolled

Leukemia, Leukemia, Myeloid, Acute

NCT01446133 2026-01-27

Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)

120 enrolled

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06768476 2026-01-16

AML

12 enrolled

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT04874480 2026-01-09

Tegavivint for the Treatment of Relapsed or Refractory Leukemia

9 enrolled

Leukemia

NCT01746849 2026-01-07

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

LymphoidMyeloidOther hematologic neoplasmPlasma cell

82 enrolled

Leukemia, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes

NCT02787369 2026-01-07

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

3 enrolled

Leukemia, Leukemia, B-Cell

NCT05199051 2026-01-05

AGORA-1

19 enrolled

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT03330691 2025-12-15

A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia

78 enrolled

Phase 2/3 Active not recruiting

Leukemia, Lymphoma

NCT01046825 2025-12-10

Mature B-Cell Lymphoma And Leukemia Study III

128 enrolled 12 charts

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin

NCT02932280 2025-12-05

Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment

CNSLymphoidOther hematologic neoplasm

14 enrolled

Disease, Leukemia, Lymphoma, Recurrence, Central Nervous System Neoplasms

NCT03117751 2025-12-05

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Phase 2/3 Active not recruiting

790 enrolled

Leukemia, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03573700 2025-11-18

Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia

24 enrolled 9 charts

Phase 3 Active not recruiting

Leukemia, Leukemia, Lymphoid, Recurrence, Leukemia, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03173248 2025-11-10

AGILE

146 enrolled 11 charts 2 FDA

Leukemia, Leukemia, Myeloid, Acute

NCT02323867 2025-10-31

AB-CliniMACs

Classical hematologyLymphoidOther hematologic neoplasm

140 enrolled

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma

NCT03016377 2025-10-27

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

17 enrolled

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02251548 2025-10-24

iFCR

85 enrolled 17 charts

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00881920 2025-10-21

CHARKALL

LymphoidOther hematologic neoplasmPlasma cell

54 enrolled

Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Plasma Cell

NCT03057054 2025-10-06

Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant

Phase 3 Active not recruiting

173 enrolled 12 charts

Leukemia, Lymphoma

NCT03770429 2025-09-29

AZD6738 for Patients With Progressive MDS or CMML

MyeloidOther hematologic neoplasm

52 enrolled

Leukemia, Myelodysplastic Syndromes

NCT02935257 2025-09-23

ALLCAR19

72 enrolled

Leukemia, Lymphoma

NCT05993949 2025-09-23

Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia

8 enrolled

Phase NA Active not recruiting

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06026046 2025-09-19

EscrimHEMA

80 enrolled

Leukemia, Lymphoma

NCT05823571 2025-09-18

Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

LymphoidMyeloidOther hematologic neoplasmPlasma cell

32 enrolled

Leukemia, Leukemia, Plasma Cell, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Prolymphocytic, T-Cell, Leukemia, Myelomonocytic, Chronic

NCT01920737 2025-09-16

A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia

39 enrolled

Phase NA Active not recruiting

Leukemia

NCT05871008 2025-09-15

Integrated Actionable Aging Assessment for Cancer Patients Pilot

35 enrolled

BreastGenitourinaryLymphoidOther hematologic neoplasmPlasma cell

Urinary Bladder Neoplasms, Breast Neoplasms, Hodgkin Disease, Kidney Neoplasms, Leukemia, Leukemia, Lymphoid, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Multiple Myeloma, Prostatic Neoplasms

NCT03162536 2025-09-08

ARQ 531-101